

Index

- A1C, S5, S6, S7, S12, S20, S24, S25, S26, S27, S56, S57, S59
 advantages of, S22
 age and, S23
 alternatives to, **S112**
 cardiovascular disease and, S116–S117
 by CGM, **S112, S113–S114**
 confirming diagnosis with, S22
 correlation with BGM, S112
 diabetes distress and, S94
 equivalent eAG levels, S112
 for diabetes screening and diagnosis, S21–S22
 glycemic assessment by, S7, **S112**
 hemoglobinopathies and, S22
 in children, **S30, S263–S264, S268, S269, S270–S271**
 in cystic fibrosis-related disease, S31
 in gestational diabetes mellitus, S34–S35
 in hyperglycemia, S64
 in people with HIV, **S30**
 in preclinical type 1 diabetes, S43
 in staging type 1 diabetes, S24, S25
 limitations, S7, S112
 microvascular complications and, **S115–S116**
 in prediabetes, S27–S28, S43–S44
 in pregnancy, S22, **S285–S286**
 other conditions affecting, S22
 periodontal disease and, S69
 point-of-care assays S21, S22, S112
 race/ethnicity and, **S22, S79**
 recommendations, **S21–S22**
 serum glycosylated protein assays versus, **S112**
 setting and modifying goals for, **S113–S118**
 sleep and, S97
- AABBCC approach, S23
 acarbose, S68, S154, S174
 access to care, S14
 access to insulin, S308
 ACCORD study, S60, S64, S116, S117, S118, S181, S182, S183, S192, S222, S236, S246
 ACE inhibitors, S9, S56, S184, S185, S186, S195, S202, **S205, S220, S222, S223–S224, S266, S271, S283, S289**
 acellular matrix tissues, S40
 acute kidney injury, S151–S152, S181, S183, **S186, S222**
 ADA consensus reports, S4, S9, S32, S54, S80, S88, S113, S147, S160, S164, S165, S179, S197, S202, S245
 ADA evidence-grading system, S3
 ADA Professional Practice Committee, S1, S2, S309
 ADA scientific reviews, S4
 ADA statements, S4
 ADAG study, S112
 Addison disease, S24, S59, S265
 adolescents. *see* children and adolescents.
 adrenal insufficiency, primary, S59, S265
 adult-onset diabetes. *see* Type 2 diabetes.
 ADVANCE trial, S64, S116, S117, S118, S181, S182, S183
 advocacy statements, **S307–S308**
 care of young children with diabetes in the childcare setting, S307
 diabetes and driving, S308
 diabetes and employment, S308
 diabetes care in the school setting, S308
 insulin access and affordability, S308
 affordability, of insulin, S308
 Affordable Care Act, S14, S274
 African Americans, S15, S22, S23, S26, S27, S28, S29, S87, S221
 age
 aspirin use and, S193–S194
 effect on A1C, **S23**
 in diabetes diagnosis and classification, S23–S29
 risk factor for diabetes, S29, **S30**
 statin treatment and, S188
 agricultural workers, migrant, S15–S16
 AIM-HIGH trial, S192
 albiglutide, S204, S205, S206
 albuminuria, S9, S85, S87, S90, S119, S165, S180, S182, S185, S186, S193, S195, S199, S205, S207, 209–210, S219, S220, **S221, S222–S227, S265, S267, S273**
 alcohol intake, S6, S55, S59, S65, S81, **S86, S98, S119, S154, S184, S191, S235, S237, S283**
 algorithms
 for diabetic retinopathy screening, S232
 insulin dosing, S126, S133, S135, S222, S246, S288, S296
 to predict hypoglycemia, S300
 alirocumab, S188, S189, S190
 alogliptin, S172, S196, S197, S206, S299
 alpha-glucosidase inhibitors, S46, S148, S172
 alpha-lipoic acid, S237
 ambulatory glucose profile (AGP), S113, S114, S115, S131, S286
 amputation, foot, S9, S64, S202, S203, S234, S237, S238, S239, S240
 analogs. *see* insulin analogs.
 angiotensin receptor blockers (ARBs), S9, S56, S184, S222, S266, S267, S271, S284, S289
 anti-VEGF agents, **S233–S234**
 antiplatelet agents, **S192–S194, S247**
 antipsychotics, S28, S96, S148
 antiretroviral therapies, S27, S30
 anxiety disorders, S15, S56, S91, S92, S93, **S94, S134, S154, S234, S263**
 ARRIVE trial, S193
 artificial intelligence algorithms, for diabetic retinopathy, S232
 ASCEND trial, S85, S193
 Asian Americans, S26, S27, S28, S29, S45, S149, S153
 aspart, S170, S173, S250
 aspirin therapy, S10, **S192–S194, S233, S248, S289**
 ASPREE trial, S193
 atenolol, S237, S289
 atherosclerotic cardiovascular disease (ASCVD), S57, S165, S166, S168, S169, **S179–S218**
 atorvastatin, S188, S190
 autoimmune diseases, S23, S26, **S59, S265–S266, S289**
 autoimmune type 1 diabetes, S23, S24, S32, S268
 autologous blood products, S240
 automated insulin delivery (AID) systems, S7, S8, S83, S84, S97, S116, S119, S120, S126, S127, **S133–S135, S158, S159, S160, S163, S245, S246, S262, S263, S288, S297**
 autonomic neuropathy, diabetic, S59, S89, **S90, S181, S234, S235, S301**
 balloons, implanted gastric, S149
 bariatric surgery. *see* metabolic surgery.
 basal insulin, S10, S119, **S129, S130, S131, S132, S135, S158, S159, S160, S162, S165, S169, S170, S171, S172, S173, S174, S250, S252, S253, S254, S262, S264, S285, S298, S300, S301, S302**
 bedtime dosing
 of antihypertensives, **S186**
 of insulin, S155, S162, S163, S248
 behavioral therapy, **S147–S148**
 behaviors, changes in, S6, **S77–S110**
 cost considerations for medication-taking, S6, **S13–S14**
 diabetes self-management education and support, **S77–S80**
 for diabetes prevention, **S44–S46**
 medical nutrition therapy, **S80–S86**
 physical activity, **S86–S90**
 in gestational diabetes, **S287**
 psychosocial care, **S91–S98**
 smoking cessation, **S90–S91**
 supporting positive health behaviors, **S91**
 well-being and, S13
 bempedoic acid, S8, S187, **S191**
 beta-carotene, S81, S85
 beta-cell replacement therapy, S161, S164
 biguanides, S172
 bioengineered allogeneic cellular therapies, S240
 bladder dysfunction, S235, S284
 Blood Glucose Awareness Training, S121
 blood glucose monitoring (BGM), S53, **S127–S129, S160, S163**
 in hospitalized patients, **S297**
 continuous glucose monitoring, **S129–S132**
 correlation with A1C, **S112**
 devices for, **S126–S127**
 during pregnancy, S284, **S285**
 in children and adolescents, S264, S269, S271
 in intensive insulin regimens, **S129**
 in older adults, S246, S251
 in people on basal insulin, oral agents, or noninsulin injectables, **S129**
 in schools, **S127**
 inaccuracy of, **S129**
 interfering substances, S129
 meter standards, **S128**
 optimizing device use, **S128–S129**
 surveillance of, S128
 blood pressure control. *see also* hypertension, S180–S186, S205, S219, S222
 body mass index (BMI), S7, S10, S23, S25, S26, S31, S45, S46, S47, S56, S59, S87, S88, S146, S149, S223,
 COVID-19 mortality and, S62
 effects of metformin use in pregnancy on, S287, S288, S290
 for metabolic surgery, S150, S153, S271
 in obese patients, S146–S147, S148
 in screening asymptomatic adults, S27
 in screening asymptomatic children, S27, S268
 postpartum, S290
 bone fracture risk, S59–S62, S68
 bone-strengthening activities, S86, S87, S261, S270

- breastfeeding. *see* lactation.
bromocriptine, S148, S172
- calcium channel blockers, S186, S224
canagliflozin, S62, S169, S172, S197, S200, S203, S205, S206, S207, S224, S225
cancer, risk in diabetics, **S62**
cannabis, S6, **S90–S91**,
CANVAS study, S62, S197, S200–S201, S203, S207, S224, S226
CANVAS-R study, S203
capsaicin, topical, **S236**
carbamazepine, S236
carbohydrate intake, S26, S81, S84, S86, S158, S162–S163, S261–S262, S286
cardiac autonomic neuropathy, diabetic, **S235**
cardiac function testing, **S272–S273**
cardiovascular disease, S2, S7, **S179–S218**
antiplatelet agents, **S192–S194**
cardiac testing, **S195–S196**
heart failure, S8, S9, S10, S54, S57, S63, S68, S87, S116, S117, S118, S146, S164, S166, S167, S179–S180, S180, S181, S182, S183, S193, S195, S196, S197, S199, S200–S208, S221, S224–S227
hypertension/blood pressure control, **S180–S186**
lifestyle and pharmacologic interventions, **S202–S205**
lipid management, **S186–S187**
prevention of, **S47**
risk calculator, **S180**
screening, **S194–S195**
statin treatment, **S187–S192**
treatment, **S196**
cardiovascular risk, S14, S16, S27, S33, S47, S54, S60, S63, S65, S67, S68, S85, S87, S88, S116–S117, S146, S153, S164–S165, S168, S179, **S180–S184**, S187, S188, S190, S191, S193, S194, S195–S197, S202, S204, S205, S206, S208, S210, S219–S220, S222, S223, S226, S235, S236, S245, S247, S248, S259, S261, **S266–S267**,
care delivery systems, S5
access to care and quality improvement, S14
behaviors and well-being, S13
care teams, S13
chronic care model, S12
medication cost considerations, S13–S14
six core elements, S12
system-level improvement strategies, S12–S13
telehealth, S13
care teams, **S13**, S91, S92, S93, S95, S127, S136, S273
CARMELINA trial, S196, S206
CAROLINA trial, S196, S202
celiac disease, S24, S59, S61, S259, **S265–S266**
CHAP trial, S184, S289
Charcot neuropathy, S9, S88, S90, S237, S238, S239
childcare, S10, S120, **S262**, S307
children and adolescents, S7, S9, **S258–S281**
A1C in, **S30**, S263–S264, S268, S269, S270–S271
asymptomatic, risk-based screening in, S27
cystic fibrosis-related diabetes in, S6, S21, S23, S31, S111, S135, S258, S268, S284
diabetes care in childcare settings, S10, S120, **S262**, S307
diabetes care in school setting, **S127**, S261, **S262**, S263, S268, S308
insulin pumps in, S7, S263, S270
maturity-onset diabetes of the young (MODY), S22, **S32–S33**
monogenic diabetes syndromes, **S32–S34**
neonatal diabetes, S22, **S32**, **S33**
physical activity in, S45, S86, **S87**
screening for type 1 risk, S26, **S267**
screening for prediabetes and type 2, S27, **S30**, **S268**
substance abuse, S273
transition from pediatric to adult care, **S273–S274**
type 1 diabetes in, S14, S23, S24, S46, **S261–S268**
type 2 diabetes in, **S268–S273**
CHIPS trial, S184, S289
cholesterol lowering therapy, S9, S56, S187, S190, S191
chronic care model, S11 **S12**, S52, S269
chronic kidney disease, diabetic, S8, S9, S32, S53, S54, S56, S57, S66, S87, S117, S119, S120, S161, S164, S165, S166, S180, S195, S199, **S209–S210**, **S219–S230**, S244, S248, S249, S252
acute kidney injury, S151–S152, S181, S183, **S186**, **S222**
assessing albuminuria and GFR, **S221**
diagnosis, **S221**
epidemiology, **S221**
interventions for, **S223–S227**
referral to nephrologist, **S227**
risk of progression, S223, S224, S226
screening recommendations, **S219**
staging, S221
surveillance, **S222–S223**
treatment recommendations, **S219–S221**
chrononutrition, S83
classification, S5, **S22–S23**
clonidine, S237, S289
clopidogrel, S193, S194
closed-loop systems, S135
do-it-yourself, **S135**
hybrid, S7, S8, S135, S159, S162, S246, S297
coaching, online, S78, S136
cognitive capacity/impairment, S96–S97
colesevelam, S148, S172
collaborative care, **S52–S54**, S94, S95, S197–S198
collagen vascular diseases, S59
combination therapy, S8, S164, S165, **S168–S169**, **S190–S191**, **S192**, S193, **S194**, S205, S237, S252
community health workers, S14, S16, S45, S52, S79, S91, S169
community screening, **S30**
community support, S5, S14, **S16**, S97, S262, S273
comorbidities, S6, S9, S12, S23, S32, **S43**, S47, **S52–S76**
assessment of, **S59–S69**
autoimmune diseases, S59
bone health and fractures, S59–S62
cancer, **S62**
cognitive impairment/dementia, **S62**
COVID-19, **S62–S64**
disability, **S64**
hepatitis C, **S64**
hyperglycemia, **S64**
hypoglycemia, **S64–S65**
low testosterone in men, **S65**
nonalcoholic fatty liver disease, **S65–S68**
obstructive sleep apnea, **S68–S69**
pancreatitis, **S69**
periodontal disease, **S69**
prevention or delay of, S6, **S43–S51**
sensory impairment, S77
COMPASS trial, S194
computerized prescriber order entry (CPOE), S298
CONCEPTT study, S285, S286
connected insulin pens, S126, S127, S133, S161, S263
continuous glucose monitoring (CGM), S7, S8, S9, S10, S21, S31, S53, S55, S56, S78, S83, S84, S95, S111, **S113–S117**, S126–S127, S128, S159, S162–S163, S166
ambulatory glucose profile in, S113, S114, S115, S131, S286
assessment of glycemic status with, **S113**
benefits of, S130
devices for, **S129–S130**
in hospitalized patients, S136, **S297–S298**, **S299–S300**
in hypoglycemia prevention, S118, S121
in older adults, **S246**, S253
in pediatric type 1 diabetes, S263–S265
in pediatric type 2 diabetes, S269–S271
in pregnancy, S131–S132, S284, **S286**
initiation of device use, S127
interfering substances, S132
intermittently scanned devices, S7, S78, S94, S129–S130, **S131**, S263, S264, S269
real-time, S7, S94, S121, S129, S130, S263, S254, S269, S284, S286, S297
side effects, S132
continuous subcutaneous insulin infusion (CSII), S126, S127, S129–S130, S133, S135, S159, S160, S161
contraception, S149, S152, S259, S260, S263, S266, S267, S271, S272, S273, S282–S283, S284, S289, **S291**
coronary artery disease, S88, S184, S185, S186, S194, S197, S202, S205
cost considerations, **S13–S14**, S149–S153, S159–S160, S165, S169, S170, S173
counterfeit test strips, S128
COVID-19, S5, S6, S26, S28, **S54–S56**, **S62–S64**, S80, S297
COVID-19 vaccines, S56, S58, S64–S65, S285
CREDENCE study, S62, S200–S201, S203, S207, S225, S226
cystatin C, S221
cystic fibrosis-related diabetes, S6, S21, S23, S31, S111, S135, S258, S268, S284
Da Qing Diabetes Prevention Outcome Study, S44, S47, S48
DAPA-CKD study, S200–S201, S203, S225, S226
DAPA-HF study, S200–S201, S203, S206, S207
dapagliflozin, S62, S63, S169, S172, S200–S201, S203, S204, S206, S207, S225, S226
DARE-19 study, S63
DASH diet, S45, S82, S184, S186
DECLARE-TIMI 58 study, S200–S201, S203, S207, S226
degludec, S159, S170, S172, S174, S250, S298
delay, of symptomatic type 1 diabetes, S48
delay, of type 2 diabetes, S5–S6, **S43–S51**
lifestyle behavior change, **S44–S46**
person-centered care goals, **S47–S48**
pharmacologic interventions, **S46–S47**
recommendations, S43, S44, S46, S4, S487
of vascular disease and mortality, **S47**
DELIVER study, S200–S201, S204, S207
dementia, in diabetics, S62, S64, S65, S69, S96, S119, S192, S245–S246

- demographics, of diabetes care, S12–S14
dental practices, screening in, S30, S55, S57
depression, S7, S15, S56, S88, S91, S92, S93, S94, **S95**, S97, S134, S150, S154, S234, S236, S244, S245, S248, S251, S263, S273
detemir, S162, S170, S173, S250
devices. *see* technology.
Diabetes Control and Complications Trial (DCCT), S21, S22, S69, S116, S159, S264, S267
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), S69, S117, S120, S246
diabetes distress, S6, S9, S12, S15, S56, S91, S92, **S93–S94**, S130, S159, S262, S263, S273, S303
diabetes medical management plan (DMMP), for students, S127
Diabetes Prevention Impact Tool Kit, S45
Diabetes Prevention Program (DPP), S27, S28, **S44**, S45, S46, S48, S86, S136
Diabetes Prevention Program Outcomes Study (DPPOS), S28, S44, S46, S48, S47, S86, S168
Diabetes Prevention Recognition Program (DPRP), S46
diabetes self-management education and support (DSMES), S6, S13, S16, S54, **S77–S80**, S82, S94, S172
diabetes technology. *see* technology, diabetes.
diabetic ketoacidosis, S10, S23, S63, S64, S88, S91, S93, S96, S121, S131, S159, S168, S203, S208, S253, S261, S270, S284, S288, S298, **S301–S302**
diabetic kidney disease. *see also* chronic kidney disease.
dietary protein and, S75
diagnosis, S221
physical activity and, **S90**
finerenone in, S202, **S206**, **S209–S210**, S225, S226–S227
glucose-lowering medications for, S224–S227
multiple drug therapy, S186
prevention, S222
screening for complications of, S223
Diabetic Retinopathy Study (DRS), S234
diagnosis, S5, S6, **S20–S37**
confirmation of, S22
criteria for, S21
cystic fibrosis-related, S22, **S31**
diabetic kidney disease, S221
diagnostic tests, S20–S22
gestational diabetes, S34–S37
maturity onset diabetes of the young (MODY), S32, S33
monogenic diabetes syndromes, **S32–S34**
neonatal diabetes, S32
posttransplantation diabetes mellitus, **S31–S32**
prediabetes and type 2, **S26–S31**
type 1, **S24–S26**,
diagnostic tests, S20–S22
A1C use as, **S21–S22**
confirmation of, S22
criteria for, S21
fasting plasma glucose (FPG) test, S20, **S21**, S22, S23, S24, S26, S27, S30, S32, S34, S35, S36, S171
oral glucose tolerance test (OGTT), S20, S21, S22, S26, S27, S31, S32, S33, S34, S35, S36, S286, S290
plasma glucose test, 2-h, S20, **S21**, S23, S24, S26, S27, S30, S33, S35
diet, *see* Medical nutrition therapy.
Dietary Reference Intakes, S287
DIAMOND trial, S246
digital health technology, **S136**
dipeptidyl peptidase 4 (DPP4) inhibitors, S62, S68, S148, S166, S167, S168, S172, S196, S202, S250, S252, S298
disordered eating behavior, S56, S82, S84, S91, S92, S93, **S95–S96**, S261, S262, S263, S273, do-it-yourself systems, **S135**, S159
domperidone, S237
Dose Adjusted for Normal Eating (DAFNE), S121
DRCR Retina Network, S233
driving, and diabetes, S308
droxidopa, S237
dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP), S8, S68, S148, S149, S165, S167, S168, S169, S170, S171, S172, S174, S252
dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, S8, S62, S68, S148, S149, S165, S167, S168, S169, S170, S171, S172, S174, S252
dulaglutide, S165, S169, S172, S198, S204, S205, S206, S232,
duloxetine, S236
dyslipidemia, S12, S13, S27, S28, S47, S56, S66, S87, S96, S97, S148, S179, S180, S191, S192, S193, S202, S231, S234, S236, S248, S259–S260, **S266–S267**, S270, S272
e-cigarettes, S6, **S90–S91**
eating disorders, S82, S95, S263
eating patterns, S6, S44–S45, S53, S55, S68, S80, S81, **S82**, S84, S85, S93, S95, S96, S269, education, *see also* diabetes self-management education and support (DSMES).
on device use, **S127**
patient, S7, S13, S16, S120, S121, S239, S264
preconception, S262, S263, S273, **S282–S283**, S284
staff, S10, S128, S253, S297
electrical stimulation, gastric, S237, S240
ELIXA trial, S198–S199, S204
EMPA-REG OUTCOME trial, S200, S201, S203, S206–S207, S224
empagliflozin, S10, S62, S169, S172, S200–S201, S203–S204, S205, S206, S207, S224, S226, S269, S270, S271
EMPEROR-Preserved trial, S200–S201, S203, S207, S226
EMPEROR-Reduced trial, S200–S201, S203, S207, S226
employment, diabetes and, S308
enalapril, S205, S237
end-of-life care, S248, **S254**
enteral/parenteral feedings, S298, **S300–S301**
erectile dysfunction, S65, S235, **S237**
ertugliflozin, S62, S172, S200, S204, S205, S299
erythromycin, S237
erythropoietin therapy, A1C and, S22, S247
estimated average glucose (eAG), S112
ETDRS study, S233, S234
ethnicity, S2, S12, S15, S23, S25, S27, S28, S30, S34, S45, S62, S63, S64, S79, S112, S262, S268
evidence-grading system, S3
evolocumab, S188, S189, S190–S191
EXAMINE trial, S196, S197, S206
exenatide, S172, S198, S205, S206
exercise. *see* physical activity.
exocrine pancreas diseases, S6, S30, S69
EXSCEL trial, S198–S199, S205,
eye exam, S55, S57, S232, S267, S272, S283
ezetimibe, statins and, S187, **S189**, S190, S192
family history, S23, S25, S26, S27, S28, S32, S34, S55, S59, S62, S95, S180, S193, S268, S271
farmworkers, migrant and seasonal, S15–16
fasting, S6, S10, S20, S21, S23, S25, S35, S36, **S83**, S119, S127,
fasting plasma glucose (FPG) test, S20, **S21**, S22, S23, S24, S26, S27, S30, S32, S34, S35, S36, S171
fats, dietary, S6, S81, **S85**, S154, S266, S272, S284, S285, S287,
FDA standards, for glucose meters, S128
fear, of hypoglycemia, S56, S91, S92, S93, S94, S119, S121, S159, S244, S263
fenofibrate, S192, S234
fibrate, S260, S272
plus statin therapy, **S192**
fibrosis-4 index, S65, S66, S67,
FIDELIO-DKD trial, S206, S209, S226, S227
FIGARO-DKD trial, S206, S209, S227
finerenone, S195, S202, **S206**, **S209–S210**, S225, S226–S227
fish skin graft, S240
FLOW trial, S266
fluvastatin, S188
food insecurity, S15
foot care, S9, **S237–S241**, S268
footwear, S90, S237, S239
FOURIER trial, S189
fracture risk, S6, S59, S60–S62, S68,
gastrectomy, vertical sleeve, S153
gastric aspiration therapy, S149
gastric bypass, Roux-en-Y gastric, S153
gastric electrical stimulation, S237
gastrointestinal neuropathies, **S235**
gastroparesis, S8, S235, **S237**, S252
gemfibrozil, S192
genetic testing, S25, S32–S33, S66
genitourinary disturbances, **S235**
gestational diabetes mellitus (GDM), S10, S23, S27, **S34–S37**, S45, S46, S47, S81, S88, S95, S97, S132, S232–S233, **S286–S288**
definition, S34
diagnosis, S35–S36
insulin, **S288**
lifestyle and behavioral management, S287
management of, **S286–S288**
medical nutrition therapy, S287
metformin, S287
one-step strategy, S35
pharmacologic therapy, S287–S288
physical activity, S287
postpartum care, S290
screening, S35–S36
sulfonyleureas, S287
two-step strategy, S37
glargine, S159, S162, S169, S170, S172, S173, S174, S250, S298
glimepiride, S169, S172, S196, S202
glipizide, S172, S252
glomerular filtration rate, S8, S9, S56, S61, S85, S119, S161, S165, S166, S167, S168, S185, S186, S195, S196, S199, S201, S219, S220, **S221**, S223, S225, S250, S267, S271
glucagon, S7, S8, S31, S118, **S120–S121**, S158, S169, S170, S208, S224, S225, S231,
glucagon-like peptide 1 receptor agonists (GLP-1 RA), S8, S28, S62, S67, S68, S116, S148, S151, S152, S160, S164, S166, S167, S171, S172, S173, S195, S196, S199, S204, S209, S220, S245, S249, S269, S270, S299
glucocorticoid therapy, **S301**

- glucose meters, S7, S119, S127, S128–S129
 counterfeit strips, S128
 inaccuracy, S129
 interfering substances, S129
 optimizing use of, S128
 oxygen, S129
 standards, S128
 temperature, S129
- glucose monitoring. *see* blood glucose monitoring.
- glucose-6-phosphate dehydrogenase deficiency, A1C and, S22, S112,
- glucose-lowering therapy, S33, S148, S165
 glulisine, S173, S250,
 glyburide, S10, S172, S252, S286, S287
- glycemic goals, S7, S8, S9, S10, **S111–S125**
 assessment of glycemic status, **S111–S113**
 cardiovascular disease outcome with, **S116–S117**
 continuous glucose monitoring, **S113–S114**
 for nonpregnant adults, **S116**
 in diabetic kidney disease, **S223**
 in hospitalized patients, **S296–S297**
 in pregnancy, **S284–S285**
 hypoglycemia, **S118–S121**
 intercurrent illness, **S121**
 in older adults, S246–S249
 in pediatric type 1 diabetes, **S263–S265**
 in pediatric type 2 diabetes, **S269**
 setting and modifying A1C goals, S117–S118
- glycemic treatment, S7, **S158–S178**
 for adults with type 1 diabetes, S158–S164
 for adults with type 2 diabetes, S164–S174
 growth factors, S240
 guanfacine, S237
- health literacy, S14, S15, **S16**, S80, S119, S247, S262, S273
- health numeracy, S13, S14, S15, **S16**, S53, S79, S80, S83, S84, S162, S247, S261
- health promotion, S11–S19
- hearing impairment, S69
- heart failure, S8, S9, S10, S54, S57, S63, S68, S87, S116, S117, S118, S146, S164, S166, S167, S179–S180, S180, S181, S182, S183, S193, S195, S196, S197, S199, S200–S208, S221, S224–S227
- hemodialysis, A1C and, S22, S247
- hemoglobinopathies, A1C and, S35, S44, S55, S268
- hepatitis B, S222, S284
- hepatitis B vaccines, **S56**, S58, S284
- hepatitis C infection, **S64**, S284
- hepatitis, autoimmune, S24, S265
- high-intensity interval training, S6, **S88**
- Hispanic/Latino population, S15, S22, S27, S28, S79, S87
- homelessness, S5, S14, **S15**, S55, S119, S262, S273
- hospital care, S10, **S295–S306**
 care delivery standards, **S295–S296**
 continuous glucose monitoring, **S297**
 diabetes care specialists in, S296
 diabetic ketoacidosis, **S301–S302**
 enteral/parenteral feedings, **S300**
 glucocorticoid therapy, **S301**
 glucose-lowering treatment in, **S298–S299**
 glucose monitoring, **S297–S298**
 glycemic goals in, **S296–S297**
 hyperosmolar hyperglycemic state, **S301–S302**
 hypoglycemia, **S299–S300**
 insulin therapy, S298–S299
- medical nutrition therapy in, **S301**
 medication reconciliation, S302
 noninsulin therapies, S299
 perioperative care, S301
 preventing admissions and readmissions, **S303**
 self-management in, **S300**
 standards for special situations, **S300–S301**
 structured discharge communication, S302
 transition to ambulatory setting, S295, **S302–S303**
- HOT trial, S182, S183
- housing insecurity, S5, **S15**
- HPS2-THRIVE trial, S192
- human immunodeficiency virus (HIV), S22, S23, S26–S27, **S30**, S235, S284
- human regular insulin, S170, S173, S301, S302
- hybrid closed-loop systems. *see* automated insulin delivery systems.
- hydrogel, oral, S149
- hyperbaric oxygen therapy, S239, S240
- hyperglycemia, S10, S15, S21, S22, S23, S24, S25, S26, S28, S30, S31–S32, S34, S35, S47, S63, **S64**, S67, S68, S69, S83, S86, S88, S95, S97, S111, S113, S115, S121, S127, S128, S131–S132, S135, S146, S153, S165, S168, S170, S171, S221, S231, S232, S246, S247, S248, S251, S253, S254, S261–S262, S264, S269, S272, S282, S284, S285, S286, S290, S295, S296, S297, S298–S299, S301–S302
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, S36, S285
- hyperosmolar hyperglycemic state, S10, S64, S121, S247, S269, S270, S298, S301–S302
- hypertension, S9, S12, S13, S27, S28, S45, S47, S57, S65, S66, S85, S87, S88, S97, S116, S146, S148, S159, S179, **S180–S186**, S193, S199, S202, S205, S221, S222, S223, S224, S225, S227, S231, S236, S244, S247, S248, S250, S254, S259, S260, S266, S270, **S271**, S272, S282, S284, S286, S288, S289
- hypertriglyceridemia, S85, S159, S168, S191
- hypoglycemia, **S64–S65**, **S118–S125**, S129, S130–S132, S134–S135, S136, S150–S154, S158–S165, S168–S169, S170, S174, S203, S208, S210, S223, S234, S235, S244, **S245–S246**, S249–S250, S251, S252, **S253–S254**, S261–S265, S269, S282, S282–S288, S291, S295, S296–S297, S298, **S299–S300**, S301–S302
- hypogonadism, S65, S237
- hypokalemia, S186, S220, S222
- icosapent ethyl, S85, S191, S225
- idiopathic type 1 diabetes, **S27**
- illness, intercurrent, glycemic targets in, **S121**, S129
- immune checkpoint inhibitors, S23, S26
- immune-mediated diabetes, **S24**
- immunizations, **S54–S59**
- impaired fasting glucose (IFG), S21, S24, S27, S28, S43, S48
- impaired glucose tolerance (IGT), S21, S24, S27, S28, S36, S43, S47, S48
- inclisiran, S9, S187, S189–S191
- incretin-based therapies, S31, S69, **S252**
- Indian Diabetes Prevention Program (IDPP-1), S46
- infections, S5, S26, S31–S32, S54–S59, S63, S64, S90, S134, S235, S239, S251, S252, S301
- influenza vaccines, **S56–S57**, S58
- inhaled insulin, S8, S133, S158, S160, S173
- injection techniques, S133, S161, **S160–S161**
- inpatient care. *see* hospital care.
- insulin analogs, S8, S134, S158, S159, S162, S169, S170, S174, S252, S264, S298, S302
- insulin delivery, S7, S8, S57, S83, **S132–S136**
 automated systems, S7, S8, S83, S84–S85, S97, S116, S119, S120, S126, S127, S135, S158, S159, S160, S163, S245, S246, S262, S263, S288, S297
- do-it-yourself closed-loop systems, **S135**, S159
- injection techniques, S133, S161, **S160–S161**
- IV, transitioning to SC, **S298–S299**
- pens and syringes, **S132–S133**
- pumps, **S133–S136**
- insulin pump therapy, S128, S130, S131, **S133–S136**, S160, S162, S264, S270
- insulin resistance, S22, S23, S25, S27, S28, S30, S31, S47, S62, S65, S66, S67, S87, S97, S170, S172, S272, S284, S285, S286, S287, S288, S289, S298
- insulin secretagogues, S81, S88, S89, S120, S148, **S252**
- insulin therapy
 access and affordability, S308
 basal, S10, S119, **S129**, S130, S131, S132, S135, S158, S159, S160, S162, S165, S169, **S170**, S171, S172, S173, S174, S250, S252, S253, S254, S262, S264, S285, S298, S300, S301, S302
 cost considerations, **S173**
 dosing algorithms using machine learning, S126, S133, S135, S222, S246, S288, S296
 in adults with type 1 diabetes, **S158–S164**
 in adults with type 2 diabetes, **S164–S174**
 combination injectable, **S174**
 concentrated insulins, **S170**, S288, S299
 in hospitalized patients, S298–S299
 inhaled insulin, S8, S133, S158, S160, S173
 in older adults, S250–S253
 prandial, S128, S160, **S170**, S171, S174, S250, S262, S270, S298, S300
 insulin:carbohydrate ratio (ICR), S162
- integrated CGM devices, S130
- intensification
 of obesity treatment, S8, S149
 of diabetes therapy, S8, S160, S164, S168, S169, S174, S197, S141, S143, S149, S151, S154, S176
- intermittent fasting, S83
- intermittently scanned CGM devices, S7, S78, S94, S129–S130, **S131**, S263, S264, S269
- International Association of the Diabetes and Pregnancy Study Groups (IADPSG), S34–S37
- islet transplantation, S161, **S164**
- isradipine, S237
- juvenile-onset diabetes. *see* immune-mediated diabetes.
- KDIGO study, S9, S80, S221, S224
- ketoacidosis, diabetic, S10, S23, S63, S64, S88, S91, S93, S96, S121, S131, S159, S168, S203, S208, S253, S261, S270, S284, S288, S298, **S301–S302**
- kidney disease. *see* chronic kidney disease.
- Kumamoto study, S116
- lactation, **S290–S291**
- language barriers, S16
- latent autoimmune diabetes in adults (LADA), S23
- Latino/Hispanic population, S15, S22, S27, S28, S79, S87

- LEADER trial, S198–S199, S204, S224
- lifestyle behavior changes, **S44–S46**
 delivery and dissemination of, **S45–S46**
 Diabetes Prevention Program, **S44**
 for diabetes prevention, **S44–S46**
 for hypertension, **S184**
 for lipid management, S186–S187
 for weight management, S147–S148
 in older adults, **S249**
 in pediatric type 1 diabetes, S259, S266–S267
 in pediatric type 2 diabetes, S259, **S268–S271**
 in pregnancy, S286
 nutrition, **S44–S45**
 physical activity, **S45**
 to reduce ASCVD risk factors, S180, S184
 type 1 diabetes progression and, **S46**
- linagliptin, S172, S196, S202–S203, S206, S271
- lipase inhibitors, S151
- lipid management, S146, **S186–S187**, **S236**, S247, S254
- lipid profiles, S56, S186, S187, S259–S260, S266, S267
- liraglutide, S46, S68, S149, S151, S164, S169, S172, S173, S174, S198, S204–S205, S206, S224, S232
- lispro, S170, S172, S173, S250
- lixisenatide, S173, S174, S198, S204, S206
- long-acting insulin, S159, S169, S170, S252, S264, S269, S270
- Look AHEAD trial, S63, S69, S83, **S147**, S202, S249
- loss of protective sensation, S235, S237, **S238**
- lovastatin, S188
- machine learning, insulin dosing algorithms using, S296
- macular edema, diabetic, S232–S234, S252
- marijuana. *see* cannabis.
- maternal history, in screening children/adolescents, S27
- maturity-onset diabetes of the young (MODY), S23, **S32–S33**, S268
- meal planning, S80, **S82–S83**, S84, S284
- Medicaid expansion, S14
- medical devices, for weight loss, **S149**
- medical evaluation, S2, S3, S6, **S52–S76**, S146, S161, S187
 autoimmune diseases, **S59**
 bone health, **S59**
 cancer, **S62**
 cognitive impairment/dementia, **S62**
 comorbidities, **S59–S62**
 comprehensive, **S54**, S55–S56
 COVID-19, **S62–S64**
 disability, **S64**
 hepatitis C, **S64**
 hyperglycemia, **S64**
 hypoglycemia, **S64–S65**
 immunizations, **S54–S59**
 low testosterone in men, **S65**
 nonalcoholic fatty liver disease, **S66–S68**
 nonalcoholic steatohepatitis, **S66–S68**
 obstructive sleep apnea, **S68–S69**
 pancreatitis, **S69**
 periodontal disease, **S69**
 sensory impairment, **S69**
 statins, **S69**
- medical nutrition therapy, S6, S45, S54, S57, S77, **S80–S88**, S113, S128, S154, S187, S259–S260, S261, S285
 alcohol, **S86**
 carbohydrates, **S84–S85**
 eating patterns and meal planning, **S82–S83**
 fats, **S85**
 food insecurity and access, **S82**
 goals of, **S80**
 in children and adolescents with type 1 diabetes, **S261**
 in hospitalized patients, **S301–S302**
 in pregnancy, **S287**
 micronutrient, and supplements, **S85–S86**
 nonnutritive sweeteners, **S86**
 protein, **S85**
 sodium, **S85**
 weight management, **S80–S82**
- Mediterranean diet, S6, S45, S68, S81, S82, S85, S186
- meglitinides, S9, S115, S117, S119, S148, S165, S172, S245, S249, S252
- mental health. *see* Psychosocial care.
- mental health referrals, S93, S95, S96
- mental illness, serious, **S97**
- metabolic surgery, S7, S8, S10, S58, S67, S68, S80, S93, S145, S146, S148, **S149**, **S153–S154**, S164, S168, **S271**
- metformin, S10, S46–S47, S56, S61–S62, S63, S68, S86, S116, S117, S148, S161, S165, S168, S169, S170, S172, S195, S196, S198, S200, S206, S210, S224, S225, S245, **S250–S252**, S260, S269, S270–S271, S272, S286, **S287–S288**, S290, S301,
- metoclopramide, S237
- metoprolol, S206, S237
- micronutrients, S80, S81, S83, **S85–S86**
- microvascular complications, S2, S7, S12, S28, S31, S33, S48, S55, **S90**, S96, S113, **S115–S116**, S117, S159, S164, S189, S181, S234, **S267–S268**, S270, S283,
- midodrine, S237
- miglitol, S172
- migrant farmworkers, S15–S16
- mineralocorticoid receptor antagonist therapy, S8, S185, S186, S220, S222, S223, S225, **S226–S227**
- monogenic diabetes syndromes, S22, **S32–S34**
- multiple daily injections (MDI), S55, S128, S129, S130, S131, S132, S133–S134, S135, S160, S162–S163, S270
- myasthenia gravis, S24, S59, S256
- naltrexone/bupropion ER, S150
- nateglinide, S46, S172, S252
- National Diabetes Data Group, S36
- National Diabetes Prevention Program, S45
- National Health and Nutrition Examination Survey (NHANES), S12, S35, S69, S268
- neonatal diabetes, S22, **S32**, S33, S258
- nephrologist, referral to, S220, S221, **S227**
- nephropathy, diabetic, S10, S28, S59, S60, S62, S97, S115, S164, S186, S196, S199, S201, S203, S224–S225, S231, S238, S259, S260, **S267**, S270, **S271**, S284
- neurocognitive function, **S245**
- neuropathic pain, S64, S235, **S236–S237**, S268
- neuropathy, diabetic, S9, S46, S54, S57, S59, S60, S64, S69, S86, S88, S97, S115, S116, S119, S120, S134, S169, S180, S202, **S234–S237**, S239, S259, **S267–S268**, **S272**, S284, S301
- auditory, S69
- autonomic, S59, S88, **S90**, S181, S234, S235, S301
- cardiac autonomic, **S235**
- gastrointestinal, **S235**
 genitourinary disturbances due to, **S235**
 peripheral, S46, S59, S64, **S78**, S86, **S90**, **S235**, S238
 new-onset diabetes after transplantation (NODAT), S31–S32
 niacin + statin therapy, **S192**
 nonalcoholic fatty liver disease (NAFLD), S55, S57, **S65–S68**, S284
 nonalcoholic steatohepatitis (NASH), S57, **S65–S68**, S167
 noninsulin treatments, S23, S25, S32, S68, S127, **S129**, S131, S132, **S161–S164**, S168, S169, S170, S172, S249, S250, S251, S269, S286, S295, S298, **S299**, S300, S302, S308
 noninsulin-dependent diabetes. *see* type 2 diabetes.
 nonnutritive sweeteners, S6, S81, S86
 NPH insulin, S159, S160, S163, S169, S170, S171, S172, S173, S174, S250, S252, S298, S300–S301
 nucleoside reverse transcriptase inhibitors, S32
 nursing homes, **S253–S254**
 nutrition, S6, S11, S13, S16, S22, S30, S35,
 for diabetes prevention/delay, **S44–S45**
 nutrition therapy. *see* medical nutrition therapy.
- obesity, S7–S8, S9, S10, S26, S27, S28, S30, S34, S44, S48, S55, S62, S65, S66, S67–S69, S80–S81, **S145–S157**
 assessment and monitoring, **S145–S147**
 medical devices for weight loss, **S149**
 metabolic surgery, **S149**, **S153–S154**
 nutrition, physical activity, and
 behavioral therapy, **S147–S148**
 pharmacotherapy, **S148–S149**,
 S150–S152
- obstructive sleep apnea, S55, S56, **S68–S69**, S97, S173, S186, S199, S260, **S272**
- ODYSSEY OUTCOMES trial, S189
- older adults, S9, S15, S57, S58, **S244–S257**
 bone health in, S59–S62
 end-of-life care, S254
 hypoglycemia, S245–S246
 lifestyle management, S249
 neurocognitive function, **S245**
 pharmacologic therapy, S250–S253
 in skilled nursing facilities and nursing
 homes, S253–S254
 special considerations for, S253
 treatment goals, S246–S249
 with type 1 diabetes, S245, S246
- one-step strategy, for GDM, **S35–S36**
- opioid antagonist/antidepressant combination, S150
- opioids, S236, S237
- ophthalmologist, referral to, S90, S232, S233
- oral agents. *see also specific drugs.* **S129**, S253, S254, S288
- oral glucose tolerance test (OGTT), S20, S21, S22, S26, S27, S31, S32, S33, S34, S35, S36, S286, S290
- organ transplantation, posttransplantation
 diabetes mellitus, S23, **S31–S32**
- orlistat, S46, S150
- orthostatic hypotension, S182, S234, S235, **S237**
- overweight people, S9, S10, S27, S28, S30, S44, S45, S48, S67, S80, S81, S86, S87, S116, **S146–S147**, S148, S149, S180, S249,
 children and adolescents, S9–S10, S26, S27, **S268–270**,
 during pregnancy, S284, S288, S290
 oxygen, glucose monitors and, S129
 oxygen therapy, S240
 for advanced wound care, S240

- hyperbaric, S239, S240
topical, S237, S239, S240–S241
- P2Y12 receptor antagonists, S193, **S195**
- palliative care, S248, S253, S254
- pancreas transplantation, S161, S164
- pancreatectomy, S31, S69, S135
- pancreatic diabetes, S6, **S30–S31**
- pancreatitis, S6, S23, S27, S30, S31, **S69**, S151–S152, S191, S205, S272
- paramedics, S14, S16, S45, S52, S79, S91, S169
- pens, insulin, S7, S126, S127, **S132–S133**
- periodontal disease, S30, **S69**
- perioperative care, S10, **S301**
- peripheral arterial disease, **S238–S239**
- peripheral neuropathy, S46, S59, S64, **S78**, S86, **S90**, **S235**, S238
- pernicious anemia, S24, S59
- person-centered care goals, S12, **S47–S48**, S12
- pharmacologic approaches. *see also* specific medications, medication classes.
for adults with type 1 diabetes, **S158–S164**
for adults with type 2 diabetes, **S164–S174**
for cardiovascular and renal disease, S7 **S202–S205**, S209–S210, S227
for comorbidities, S57
for hypertension, S184–S186
for lipid management, S188–S192
for neuropathic pain, S64, S235, **S236–S237**, S268
for obesity, S7, **S148–S149**, **S150–S153**
for pediatric type 2 diabetes, **S269–S271**
for smoking cessation, S90
in older adults, **S249–S253**
in pregnancy, **S287–S288**, S289
interfering substances for glucose meter readings, S129
to delay or prevent type 2 diabetes, **S46–S47**
to delay type 1 progression, **S48**
to glycemic treatment, S8, **S158–S178**
- phentermine, S46, S149, S150, S152, S271
- phentermine/topiramate ER, S150
- phosphodiesterase type 5 inhibitors, S237
- photocoagulation surgery, **S233–S234**
- physical activity, S6, S10, S11, S28, S55, S57, S61, S64, S111, S127, S128, S135, S202
exercise and youth, **S87**
for diabetes prevention, S44, **S45–S46**
frequency and type of, **S87**
glycemic control and, **S88**
high-intensity interval training, **S88**
in children with type 1 diabetes, **S261–S262**
in children with type 2 diabetes, S269
in DSMES, **S86–S90**
in obesity management, **S147–S148**
in older adults, S249
in pregnancy, **S287**
with diabetic kidney disease, **S90**
with microvascular complications, **S90**
pre-exercise evaluation, **S88**
- pioglitazone, S47, S62, S67, S68, S172
- PIONEER-6 trial, S198–S199
- pitavastatin, S188
- plasma glucose test, 2-h, S20, **S21**, S23, S24, S26, S27, S30, S33, S35
- pneumococcal pneumonia vaccine, **S57**, S58
- point-of-care assays
A1c, S21, S22, S112
blood glucose monitoring, S136, S297
- polycystic ovary syndrome, S27, S28, S260, S272, S273, S284, S286, S287
- population health, S5, **S11–S19**
access to care, S14
behaviors and well-being, S13
care teams, S13
chronic care model, S12–S13
cost considerations, S13–S14
quality improvement, S14
recommendations, S11
tailoring treatment for social context, S14–S16
status and demographics, S12
telehealth, S13
- postbariatric hypoglycemia, S154
- postpartum care, in diabetic women, **S289–S291**
- posttransplantation diabetes mellitus, S23, **S31–S32**
- pramlintide, S161, S172, S237
- prandial insulin, S128, S160, **S170**, S171, S174, S250, S262, S270, S298, S300
- pravastatin, S188
- prediabetes, S5, S10, S21
criteria defining, S22
diagnosis, S27–S28
lifestyle changes for prevention of diabetes, **S44–S46**
prevention of vascular disease and mortality, **S47**
screening in adults, S26, S27, S28–S30
screening in children and adolescents, S30
- preeclampsia, in women with diabetes, S34, S35, S184, S282, S284, S285–S286, 288
- aspirin and, S289
- pregabalin, S148, S236
- pregnancy, S10, **S282–S294**
A1C and, S22, **S285–S286**
continuous glucose monitoring in, **S286**
drug considerations in, **S89**
gestational diabetes mellitus (GDM), S23, **S34–S37**, **S287–S288**
glucose monitoring in, **S285**
glycemic goals in, **S284–S286**
insulin physiology in, **S288**
lactation, **S290**
lifestyle and behavior management, **S287**
medical nutrition therapy, **S287**
metformin in, **S287**
pharmacologic therapy, **S287–S288**
physical activity in, **S287**
postpartum care, **S289–S291**
pre-existing type 1 and 2 diabetes in, **S288–S289**
preconception care, **S283–S284**
preconception counseling, **S282–S283**
preeclampsia and aspirin, **S289**
real-time CGM device use in, **S131–S132**
retinopathy during, **S232–S233**
sulfonylureas, **S287**
- prevention, type 2 diabetes, S6, S7, S9, S14, S27, S28, **S43–S51**
lifestyle behavior change for, **S44–S43**
person-centered care goals, **S47–S48**
pharmacologic interventions, **S46–S47**
of vascular disease and mortality, **S47**
- proliferative diabetic retinopathy, S90, S233
- proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, S8, S30, S187, S188, **S189**, **S190**, S192
- protease inhibitors, A1C and, S30
- protein intake, S9, S10, **S85**, S158, S220, S223, S249, S270, S271
- psychosocial care, S6, S9, S77, **S91–S98**
anxiety disorders, **S94**
- assessment and treatment, **S92–S93**
cognitive capacity/impairment, **S96–S97**
depression, **S95**
diabetes distress, **S93–S94**
disordered eating behavior, **S95–S96**
in pediatric type 1 diabetes, S261, **S262–S263**
in pediatric type 2 diabetes, S273
referral to mental health specialist, S93, S95, S96
screening, S92
serious mental illness, **S96**
sleep health, S97
- pumps, insulin, **S133–S136**
do-it-yourself closed-loop system, S135, S159
in youth, S7, S134, S263, S270
sensor augmented, S134
- quality improvement, S5, **S14**, S295, S299
- RAAS inhibitors, S163
- race, S22, S27, S63, S64, S79, S112, S148, S196, S198, S200, S221
- rapid-acting insulin analog, S134, S135, S159, S160, S163, S170, S173, S250, S254, S262, S285, S298, S299, S301, S302
- real-time CGM devices, S7, S94, S121, S129, S130, S263, S254, S269, S284, S286, S297
- REDUCE-IT trial, S85, S191
- referrals, S6, S14, S16, S66, S78
for behavioral health professionals, S92
for community screening, S30
for comprehensive eye exam, S57, S267
for food insecurity, S82
for initial care management, S57
for local community resources, S16
for DSME, S54, S57, S78, S79
for tobacco cessation, S54
from dentist to primary care, S57
to behavioral health provider, S92, S93
to foot care specialist, S239
to gastroenterologist, S65, S69
to mental health professional, S93, S95, S96
to nephrologist, S220, S221, **S227**
to neurologist, S235
to sleep specialist, S98, S260
to registered dietitian nutritionist, S45, S57, S149, S261, S265, S283, S302
- registered dietitian nutritionist (RDN), S45, S57, S80, S82, S282, S285, S287, S288 43, S255, S257, S274
- reimbursement, S14, S45
for CGM in adults with type 2 diabetes, S9
for DSMES, S6, S78, **S79**
- religious fasting, **S83**
- repaglinide, S172, S252
- resistance training, S45, S68, S88, S249
- respiratory syncytial virus (RSV) vaccine, S57–S58
- retinopathy, diabetic, S66, S90, S115, S227, **S231–S234**, S267, S272, S283
screening, S232–S233
treatment, S233–S234
visual rehabilitation, S234
- REWIND trial, S198–S199, S204
- risk calculator, for ASCVD, **S180**
- risk management
cardiovascular disease, S8, **S179–S218**
chronic kidney disease, S9, **S219–S230**
- risk, screening for
type 1 diabetes, S26
prediabetes and type 2, S27, S29
rivaroxaban, S193, S194

- rosiglitazone, S148
Roux-en-Y gastric bypass, S153
- SAVOR-TIMI trial, S196, S206
saxagliptin, S172, S196, S206, S299
schizophrenia, S96
schools, diabetes care in, **S127**, S261, **S262**, S263, S268, S308
screening, S5, S6, S7, S9
 after acute pancreatitis, S31
 by age, S30,
 community, S30
 for cystic fibrosis-related diabetes, S31
 for gestational diabetes mellitus, S34, S36
 for neuropathy, S235–S236
 for prediabetes and type 2 diabetes, S26–S30
 for type 1 diabetes, S26
 for type 2 diabetes, S27 **S240**
 in children/adolescents, S30
 in dental practices, S30, S55, S57
 in people with HIV, S30
 medications, S30
 testing interval, S30
 use of A1C for, S21–S22
 use of FPG or 2-h PG for, S21
seasonal farmworkers, S15–S16
self-monitoring of blood glucose (SMBG). *see*
 blood glucose monitoring (BGM)
semaglutide, S8, S46, S68, S148, S149, S150, S165, S168, S169, S172, S198–S199, S204, S205, S206, S224–S225, S226, S232, S252
sensor-augmented pumps, S134
sensory impairment, S69
setmelanotide, S149
sexual dysfunction, S235
sickle cell disease, A1C and, S22, S112, S284
simvastatin, S188, S189, S192
sitagliptin, S169, S172, S196, S206
skilled nursing facilities, S251, **S253–S254**
sleep health, S7, **S97–S98**
smart pens. *see* connected insulin pens
smoking cessation, S6, S10, S47, S55, S59, S77, **S90–S91**, **S273**
social capital, S5, S14, **S15**
social context, S14–S16
social determinants of health (SDOH), S12, S13, S14–S15, S16, S79, S92, S166
sodium channel blockers, S235, **S236**
sodium intake, S81, S84, **S85**, S184, S223
sodium-glucose cotransporter 2 (SGLT2) inhibitors, S8, S28, S62, S68, S84, S116, S148, S164, S166, S167, S172, S180, S195, S201, S209, S220, S222, S225, S246, S250, **S252**, S270, S299
SOLOIST-WHF trial, S208
sotagliflozin, S206, S207, **S208**
SPRINT trial, S181, S182, S183, S205
staging
 of diabetic kidney disease, S57, **S221–S222**
 of type 1 diabetes, S24
statin therapy, S8, S9, S47, S67–S68, S116, S180, S187, **S187–S192**,
 combination therapy with, S190–S191
 diabetes risk with, **S192**
 high- and moderate intensity, S188
 intolerance to, S190
 primary prevention, **S187**, **S188**
 secondary prevention, **S188–S189**
 with bempedoic acid, S8, S187, **S191**
 with ezetimibe, S189
 with fibrate, S169, **S170**, **S192**
 with niacin, S169, **S170**
 with PCSK9 inhibitors, S189–S190
statins, S26, S30, **S57**, **S69**, S85, S192, S197, S198, S202
stem cell therapies, for wounds, S240
strength training, S44, S269
sulfonylureas, S9, S15, S32, S33, S62, S68, S113, S115, S116, S117, S119, S120, S148, S165, S168, S172, S174, S245, S249, S250, S252, **S287**
supplements, dietary, S61, S81, **S85–S86**, S141, S148, S154, S283, S284
surveillance
 behavioral risk factor surveillance system, S79, S94
 BGM system, S128
 for foot problems, S237, S238–S239
 of chronic kidney disease, **S222–S223**
 of NAFLD patients, S66
SUSTAIN-6 trial, S198–S199, S204, S224
sweeteners, nonnutritive, S6, S81, S86
sympathomimetic amine anorectics, S150
 in combination with antiepileptic, S150
syringes, insulin, **S132–S133**
- tapentadol, **S236**
technology, diabetes, S7, S8, S13, **S126–S144**
 blood glucose monitoring, **S127–S129**
 continuous glucose monitoring devices, **S129–S132**
 general device principles, **S126–S127**
 insulin delivery, **S132–S137**
technology-assisted prevention programs, S44, S45–S46, S79, S94
TECOS trial, S196, S206
TEDDY study, S26, S46
telehealth, S6, **S13**, S15, S45, S78–S80, S286
temperature
 of glucose monitor, S129
 perception of, S56, S234, S235, S237, S238
teplizumab, S48
testing interval, S30
testosterone
 in diabetes prevention, S46
 low, in men, **S65**
tetanus, diphtheria, pertussis (TDAP) vaccine, S58, S284
thiazide-like diuretics, S185, S186, S224
thiazolidinediones, S46, S59, S60, S148, S165, S206, S245, **S252**
thyroid disease
 autoimmune, S33, S59, S266
 in pediatric type 1 diabetes, S259, **S265**
time-restricted eating, S83
tirzepatide, S46, S62, S68, S148, S149, S152, S165, S168, S169, S172, S252
tobacco use/cessation, S6, S10, S47, S55, S59, S77, **S90–S91**, **S273**
training
 blood glucose awareness, S121
 health professionals/staff, S10, S13, S16, S79
 high-intensity interval, S6, **S88**
 on device use, S10
 resistance, S6, S44, S45, S68, S79, S88
 self-care, S16
 strength, S44, S269
tramadol, **S236**
transfusion, A1C and, S22, S112, S247
transition
 from hospital to ambulatory setting, S295, **S302–S303**
 from IV to SC insulin, **S298–S299**
 from pediatric to adult care, S258, **S273–S274**
transplantation
 islet, S161, **S164**
 liver, S65, S66
 organ, post-transplant diabetes mellitus after, S23, **S31–S32**
 pancreas, S161, **S164**
 renal, S161, S164, S196, S201, S207, S208, S221, S225
tricyclic antidepressants, S148, S235, **S236**
TWILIGHT trial, S194
two-hour plasma glucose (2-h PG) test, S20, **S21**, S23, S24, S26, S27, S30, S33, S35
two-step strategy, for GDM, **S36**
type 1 diabetes, S5, S6, S7, S8, S9, S10, S13, S14
 beta-cell replacement therapy, S161, S164
 in children/adolescents, **S233–S240**
 classification, S22–S23
 diagnosis, **S24–S26**
 idiopathic, S27
 immune-mediated, **S24**, **S26**
 in hospitalized patients, S296, **S298**, S300
 lifestyle and progression of, S46
 insulin therapy, S158, **S159–S160**
 noninsulin treatments, **S161**, **S164**
 in older adults, S245, 246
 peripheral neuropathy in, S234–S236
 pregnancy in women with preexisting, S283, S284, S285, S286, **S288**, S290
 retinopathy in, S232
 screening, S26
 staging, S24
 subcutaneous insulin regimens, S159–S161, S163–S164
 surgical treatment, **S164**
 teplizumab to delay symptoms. S48
type 2 diabetes, S5, S6, S7, S8, S9, S10, S12, S13, S15, S22–S23
 in children/adolescents, **S268–S273**
 classification, **S20–S22**
 combination therapy, S8, S164, S165, **S168–S169**, **S190–S191**, **S192**, S193, **S194**, S205, S237, S252
 diagnosis, **S26–S31**
 insulin pump use in, S135
 obesity and weight management, S29, S67, **S145–S157**, S165, S168
 pharmacologic treatment in adults, **S164–S174**
 pregnancy in women with preexisting, **S288–S289**
 prevention or delay, S6, S7, S9, S14, S27, S28, **S43–S51**
 retinopathy in, S233
 risk test for, S29
 screening in asymptomatic adults, S27, S28, S29
 screening in children/adolescents, S28, S30
 surgical treatment for, S164
type 3c diabetes, S30
- UK Prospective Diabetes Study (UKPDS), S116, S117, S197, S205
ulcers, foot, S9, S56, S88, S90, S234, **S237–S241**
ultra-rapid-acting insulin analogs, S159, S160, S163
ultrasound wound debridement, S240
- vaccines. *see* immunizations.
vagus nerve stimulator, S149
vascular disease, S90, S116, S117, S181, S183, S192, S194, S202, S237
 prevention of, in prediabetes, **S47**
VERIFY trial, S168

- vertical sleeve gastrectomy, S153
VERTIS CV trial, S200, S201, S204
Veterans Affairs Diabetes Trial (VADT), S64, S116, S246
vildagliptin, S168
vitamin D supplementation, S46, S56, S60, S61, S81, S85–S86, S148
VOYAGER-PAD trial, S194
- weight loss surgery. *see* metabolic surgery.
weight loss/management, S7, S8, S31, S31, **S80–S82**, S83, S86, S87, S93, S96, S117, S136, **S145–S154**, S184, S186, S202, S236,
in diabetes prevention, S44–S46, S47, S48
in children/adolescents, S269, S271, S272
in older adults, S249, S251, S252
in pregnancy, S290
in type 1 diabetes, S46, S61, S161
in type 2 diabetes, S29, S67, S165, S168
medical devices for, **S150**
metabolic surgery for, **S149, S153–S154**
pharmacotherapy for, **S148–S149**, S150–S152
with NAFLD, S67–S68
- unexpected, S21, S23, S20, S24, S28, S62, S95, S253
well-being, S6, **S13**, S35, S53, S65, **S77–S110**, S146, S234, S263
whites, non-Hispanic, S22, S25, S27, S60, S63, S112, S196, S198, S200,
WISDM trial, S246
Wound therapy, advanced, S239–S241
- Youth. *see* Children and adolescents.
- zoster vaccine, S59